fenofibrate has been researched along with Cardiac Failure in 13 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to observe the effects of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes." | 8.31 | Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes. ( Liu, J; Liu, X; Wang, Y; Zhang, J; Zhou, W, 2023) |
| "Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis." | 5.72 | Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. ( Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F, 2022) |
| "Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes." | 5.42 | Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015) |
| "Inflammation is implicated in chronic heart failure (CHF)." | 5.35 | Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. ( Chen, JW; Huang, WP; Jen, HL; Lin, SJ; Yin, WH; Young, MS, 2009) |
| "This study was to observe the effects of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes." | 4.31 | Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes. ( Liu, J; Liu, X; Wang, Y; Zhang, J; Zhou, W, 2023) |
| "Sprague-Dawley rats were randomly divided into normal control, obesity and fenofibrate group." | 3.78 | High free fatty acids level related with cardiac dysfunction in obese rats. ( Pan, H; Sun, X; Tan, H; Yu, Y, 2012) |
| "For patients with type 2 diabetes at high CV risk but no CKD, fenofibrate therapy added to statin reduced the CV mortality and the rate of fatal and non-fatal CHF." | 2.84 | Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. ( Applegate, WB; Cushman, W; Doumas, M; Lovato, L; Mottle, A; Nylen, E; Papademetriou, V; Punthakee, Z; Tsioufis, C, 2017) |
| "Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis." | 1.72 | Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. ( Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F, 2022) |
| "Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes." | 1.42 | Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015) |
| "Treatment with fenofibrate, a PPARα agonist, normalized both FA and glucose uptake while reducing LV dilation caused by AR." | 1.42 | Transcriptional Changes Associated with Long-Term Left Ventricle Volume Overload in Rats: Impact on Enzymes Related to Myocardial Energy Metabolism. ( Arsenault, M; Couet, J; Dhahri, W; Drolet, MC; Gascon, S; Lachance, D; Lecomte, R; Rousseau, JA; Roussel, E; Sarrhini, O; Walsh-Wilkinson, E, 2015) |
| "Inflammation is implicated in chronic heart failure (CHF)." | 1.35 | Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. ( Chen, JW; Huang, WP; Jen, HL; Lin, SJ; Yin, WH; Young, MS, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, JP | 1 |
| Vasques-Nóvoa, F | 1 |
| Ferrão, D | 1 |
| Saraiva, F | 1 |
| Falcão-Pires, I | 1 |
| Neves, JS | 1 |
| Sharma, A | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Leite-Moreira, A | 1 |
| Morieri, ML | 1 |
| Liu, X | 1 |
| Zhang, J | 1 |
| Zhou, W | 1 |
| Liu, J | 1 |
| Wang, Y | 1 |
| Huang, WP | 2 |
| Yin, WH | 2 |
| Chen, JS | 1 |
| Huang, PH | 1 |
| Chen, JW | 2 |
| Lin, SJ | 2 |
| Dhyani, N | 1 |
| Saidullah, B | 1 |
| Fahim, M | 1 |
| Omanwar, S | 1 |
| Li, P | 1 |
| Luo, S | 1 |
| Pan, C | 1 |
| Cheng, X | 1 |
| Roussel, E | 1 |
| Drolet, MC | 1 |
| Walsh-Wilkinson, E | 1 |
| Dhahri, W | 1 |
| Lachance, D | 1 |
| Gascon, S | 1 |
| Sarrhini, O | 1 |
| Rousseau, JA | 1 |
| Lecomte, R | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Papademetriou, V | 1 |
| Lovato, L | 1 |
| Tsioufis, C | 1 |
| Cushman, W | 1 |
| Applegate, WB | 1 |
| Mottle, A | 1 |
| Punthakee, Z | 1 |
| Nylen, E | 1 |
| Doumas, M | 1 |
| Jen, HL | 1 |
| Young, MS | 1 |
| Sun, X | 1 |
| Pan, H | 1 |
| Tan, H | 1 |
| Yu, Y | 1 |
| Morgan, EE | 1 |
| Rennison, JH | 1 |
| Young, ME | 2 |
| McElfresh, TA | 1 |
| Kung, TA | 1 |
| Tserng, KY | 1 |
| Hoit, BD | 1 |
| Stanley, WC | 2 |
| Chandler, MP | 2 |
| Labinskyy, V | 1 |
| Bellomo, M | 1 |
| Lionetti, V | 1 |
| Qanud, K | 1 |
| Bigazzi, F | 1 |
| Sampietro, T | 1 |
| Recchia, FA | 1 |
| Shiroshita-Takeshita, A | 1 |
| Brundel, BJ | 1 |
| Burstein, B | 1 |
| Leung, TK | 1 |
| Mitamura, H | 1 |
| Ogawa, S | 1 |
| Nattel, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients[NCT06155331] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fenofibrate and Cardiac Failure
| Article | Year |
|---|---|
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofib | 2017 |
12 other studies available for fenofibrate and Cardiac Failure
| Article | Year |
|---|---|
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glucose; Heart Failure; Hum | 2022 |
Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional Hope?
Topics: Diabetes Mellitus, Type 2; Fenofibrate; Heart Failure; Humans; Hypolipidemic Agents | 2022 |
Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes.
Topics: Chronic Disease; Diabetes Mellitus; Fenofibrate; Heart Failure; Hospitalization; Humans; Lipids | 2023 |
Fenofibrate attenuates doxorubicin-induced cardiac dysfunction in mice via activating the eNOS/EPC pathway.
Topics: Animals; Cardiomyopathies; Cardiotoxicity; Disease Models, Animal; Doxorubicin; Endothelial Progenit | 2021 |
Fenofibrate ameliorates neural, mechanical, chemical, and electrical alterations in the murine model of heart failure.
Topics: Animals; Baroreflex; Blood Pressure; Disease Models, Animal; Electrocardiography; Energy Metabolism; | 2019 |
Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate.
Topics: Animals; Cells, Cultured; Energy Metabolism; Fatty Acids; Fenofibrate; Heart Failure; Hypolipidemic | 2015 |
Transcriptional Changes Associated with Long-Term Left Ventricle Volume Overload in Rats: Impact on Enzymes Related to Myocardial Energy Metabolism.
Topics: Animals; Aortic Valve Insufficiency; Cardiac Volume; Disease Models, Animal; Energy Metabolism; Feno | 2015 |
Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study.
Topics: Aged; Blotting, Western; Cell Adhesion; Chronic Disease; Female; Fenofibrate; Heart Failure; Humans; | 2009 |
High free fatty acids level related with cardiac dysfunction in obese rats.
Topics: Angiotensin II; Animals; Biomarkers; Diet, High-Fat; Fatty Acids, Nonesterified; Fenofibrate; Heart | 2012 |
Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure.
Topics: Animals; Ceramides; Dietary Fats; Disease Models, Animal; Feeding Behavior; Fenofibrate; Heart Failu | 2006 |
Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
Topics: Acyl-CoA Dehydrogenases; Animals; Blood Pressure; Cardiac Pacing, Artificial; Cholesterol; Dogs; Ele | 2007 |
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.
Topics: Actins; Animals; Anti-Inflammatory Agents; Atrial Fibrillation; Biomarkers; Cardiac Pacing, Artifici | 2007 |